OncoMatch/Clinical Trials/NCT07761910
Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Is NCT07761910 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies multiple treatments including Coronary CT Angiography (CCTA) and 18F-Flurpiridaz for non small cell lung cancer.
Treatment: Coronary CT Angiography (CCTA) · 18F-Flurpiridaz — Prospective clinical study designed to evaluate damage to the heart after receiving standard of care chemotherapy and radiation therapy for locally advanced Non-Small Cell Lung Cancer (NSCLC).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage III
Prior therapy
Cannot have received: stereotactic body radiotherapy
Patients treated with stereotactic body radiotherapy (SBRT).
Cannot have received: thoracic radiotherapy
Prior thoracic radiotherapy.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center · Indianapolis, Indiana
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07761910 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior stereotactic body radiotherapy, thoracic radiotherapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage III is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages